An experimental obesity injection that targets three hormone receptors instead of one has produced average weight loss above 28 percent in a late-stage trial, a figure previously associated with bariatric surgery rather than medication.
Retatrutide, developed by Eli Lilly, is not approved and cannot be prescribed. The company has said it plans to submit a Biologics License Application to the Food and Drug Administration in the first quarter of 2027, which means the earliest realistic availability is later that year and could be well beyond it.
That gap between headline results and pharmacy shelves is the part patients most often miss. The trial numbers are real, and they are large. They describe a drug that regulators have not yet reviewed, priced or labeled.
Three Receptors Instead of One or Two
The distinction from current medications is mechanical rather than a matter of dosing.
Semaglutide, sold as Ozempic and Wegovy, activates the GLP-1 receptor. Tirzepatide, sold as Mounjaro and Zepbound, activates GLP-1 and GIP. Retatrutide activates GLP-1, GIP and a third receptor for glucagon.
The glucagon addition is what makes it a different category. GLP-1 and GIP signaling largely reduces how much a person eats by slowing gastric emptying and increasing satiety. Glucagon receptor activation is associated with increased energy expenditure, meaning the body uses more energy rather than simply taking in less.
Combining an appetite-reducing signal with an energy-expending one is the design logic behind calling these drugs triple agonists. Whether that mechanism accounts for the larger observed weight loss is a reasonable inference rather than a demonstrated fact, since the trials measured outcomes rather than pathway contributions.
The Trial Numbers and Their Boundaries
In TRIUMPH-1, a phase 3 trial in more than 2,300 adults with obesity or overweight plus at least one weight-related condition and without diabetes, participants on the highest 12 milligram dose lost an average of 28.3 percent of body weight over 80 weeks, about 70 pounds, from a starting average of 248.5 pounds. Those on the lowest 4 milligram dose lost 19.0 percent.
In a prespecified blinded extension for 532 participants with a body mass index of 35 or higher who continued to 104 weeks, average loss reached 30.3 percent, about 85 pounds. Lilly reported that 45.3 percent of participants on the highest dose achieved at least 30 percent weight loss, and that 65.3 percent fell below a body mass index of 30 at 80 weeks, a threshold that is analytically notable but not itself a health outcome.
Two further trials reported results more recently. In adults with type 2 diabetes, average losses ran from 12.7 percent at the lowest dose to 20.8 percent at the highest, alongside A1C reductions of up to 1.6 percentage points. In adults with severe obesity and established cardiovascular disease, average loss reached 22.6 percent at 80 weeks.
Those diabetes figures matter for expectation setting. Weight loss with incretin drugs is consistently smaller in people with type 2 diabetes than in people without it, and the same pattern holds here.
The cardiovascular question is not settled. The trial in patients with established heart disease did include prespecified analyses of major adverse cardiovascular events, but events occurred less frequently than anticipated in both groups. For a five-component composite, the hazard ratio was 0.82, with a confidence interval from 0.55 to 1.22; for a three-component composite, it was 1.12, with an interval from 0.64 to 1.96. Both intervals include the possibility of no difference, so the trial did not establish that the drug prevents heart attacks, strokes, or deaths.
Side Effects at the Doses That Produced the Largest Losses
Gastrointestinal effects, principally diarrhea and nausea, appeared at higher rates than placebo and were most pronounced at the highest doses. In the diabetes trial, diarrhea affected about a third of participants on the two higher doses, against 13.2 percent on placebo.
Discontinuation because of adverse events tracked the dose. In TRIUMPH-1, it ran 4.1 percent, 6.9 percent and 11.3 percent at the 4, 9 and 12 milligram doses, against 4.9 percent for placebo. That is the practical trade-off a clinician and patient would eventually weigh: the largest average loss came from the dose people were most likely to stop taking.
Two other effects drew attention. Abnormal skin sensation occurred more often with retatrutide than placebo, reaching 7.3 percent at the highest dose in the diabetes trial against 0.7 percent on placebo. Urinary tract infections were also more common in some comparisons, at 8.0 percent versus 6.6 percent in that trial, though the differences were smaller than the gastrointestinal ones and most events were mild to moderate and resolved during treatment.
Rapid weight loss also carries consequences that trials report incompletely. Loss of lean muscle mass alongside fat is a recognized concern across this drug class, particularly in older adults, and long-term data on bone density and nutritional adequacy remain limited.
Timeline, Cost and the Questions Still Open
"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy," said Kenneth Custer, who leads Lilly's cardiometabolic health unit. The initial trial program enrolled more than 5,800 participants across studies in obesity, obstructive sleep apnea and knee osteoarthritis pain.
Regulatory review takes time after submission, and the FDA can request additional data. Approval is not automatic even for a drug with strong efficacy results, and labeling decisions determine which patients qualify. Detailed results from the two most recent trials have not yet been published in peer-reviewed journals, which is where independent scrutiny of the dose-by-dose findings will happen.
Cost and coverage are unresolved and consequential. Current GLP-1 medications carry list prices that place them out of reach without insurance, and coverage varies widely by employer and plan. There is no reason to assume a more effective drug will be cheaper or more broadly covered.
For patients now, the reasonable position is that this is a development to watch rather than to plan around. Anyone considering treatment for obesity should discuss currently approved options with a clinician rather than waiting for a drug that has not been reviewed. Nobody should obtain compounded or imported versions of an unapproved drug from online sellers, a market that has produced dosing errors and contaminated products. Pharmacists have been advised to follow the pipeline rather than anticipate availability.
Anyone taking a current GLP-1 medication should not stop or change it based on trial results for a different drug. MedicalDaily will report the FDA submission and any regulatory action.
Key Questions Answered
What is retatrutide? An investigational once-weekly injection from Eli Lilly that activates three hormone receptors: GLP-1, GIP, and glucagon. It is not approved and cannot be prescribed.
How is it different from Ozempic or Zepbound? Semaglutide targets one receptor and tirzepatide targets two. The glucagon receptor is the addition, and it is associated with increased energy expenditure rather than reduced intake alone.
How much weight did people lose? Up to 28.3 percent on average over 80 weeks at the highest dose, and 30.3 percent over 104 weeks in a subgroup with a body mass index of 35 or higher.
Did it work as well in people with diabetes? No. Average losses in the diabetes trial ranged from 12.7 to 20.8 percent, consistent with the smaller effect seen across this drug class in people with type 2 diabetes.
Did it prevent heart attacks or strokes? Not established. The trial in patients with established heart disease recorded fewer cardiovascular events than expected, and the confidence intervals included no difference.
What are the side effects? Diarrhea and nausea occurred more often than with placebo, particularly at higher doses, and discontinuation rose with dose, reaching 11.3 percent at the highest dose in the main obesity trial.
Should anyone wait for it? No. Patients considering obesity treatment should discuss approved options with a clinician, and should not seek compounded or imported versions of an unapproved drug.
